 |
|
Cystic Fibrosis foundation lays out new treatment guidelines
November 15, 2007New clinical standards on the treatment of patients with cystic fibrosis (CF) have been released following an exhaustive review of all available literature.
The guidelines, a result of a two-year review of original research and systematic review literature from 1983 to 2006, were published in the second issue for November of the American Thoracic Society¡¦s American Journal of Respiratory and Critical Care Medicine.
CF is a complex genetic disease affecting the lungs and other organs, and is characterized by an unusually thick, sticky mucus that renders CF victims virtually incapable of fending off infections and pathogens. CF is always fatal, but thanks to advances in treatment in the last 60 years, life expectancy has increased from just a few years to 36 years. Lung disease accounts for 85 percent of the mortality among CF patients.
"Physicians treating patients with CF are faced with a growing number of treatment options" wrote lead author of the guidelines, Patrick A. Flume, M.D. "We are hopeful that clinicians will find these recommendations to be useful in their care of patients with CF."
The pulmonary guidelines committee assessed the clinical efficacy and safety of the use of aerosolized antibiotics, recombinant human DNase (dornase alfa), hypertonic saline inhalation, anti-inflammatory agents, macrolide antibiotics, the use of bronchodilators and N-acetylcysteine. They analyzed the clinical results with regard to the number of studies, strength of the study designs and the quality and consistency of results to make their final recommendations. Because of the general dearth of studies on treatments in children under the age of six, the committee restricted their recommendations to CF patients six years of age and older.
The treatments with the strongest, most consistent results yielding an "A"-grade positive recommendation were:
* Inhaled tobramycin, an antibiotic, to suppress chronic Pseudomonas aeruginosa infections in CF patients with moderate to severe disease to improve lung function and reduce exacerbations; and
* Dornase alfa, which degrades the free DNA that accumulates in CF mucus, thereby loosening the mucus, promoting airway clearance, improving lung function and reducing exacerbations.
"B" grade recommendations by the committee are for:
* Inhaled tobramycin, to suppress chronic Pseudomonas aeruginosa infections in CF patients with mild disease or who are asymptomatic, to reduce exacerbations;
* Dornase alfa, for CF patients with mild disease or who are asymptomatic, to improve lung function and reduce exacerbations;
* Hypertonic saline, which hydrates surface liquid in patients with CF, thereby improving lung function and decreasing exacerbations; and
* £]2-adrenergic receptor agonists, which relax smooth muscles and dilate bronchial passages, which improve lung-function in CF patients, and were well-tolerated.
The guidelines recommend against:
* Systemic corticosteroids in children because of "an excess number of adverse events," including abnormalities in glucose metabolism, cataracts, and percentage of patients "colonized" with Pseudomonas (this recommendation excludes patients who have concomitant asthma);
* Inhaled corticosteroids, because there was no clinical benefit (this recommendation excludes patients who have concomitant asthma); and
* Prophylactic anti-Staphylococcal antibiotics because of the lack of clinical efficacy and an apparent increase in P. aeruginosa infections with their use.
All other treatments lacked sufficient evidence to recommend for or against their use.
The article includes recommendations for physicians to help determine which therapies to use, and the order in which they should be introduced. "There is a challenge for the clinician to decide what therapy to start first, or when to add another therapy," explained Dr. Flume. "We are putting together an educational program to assist the community in implementation of the guidelines and hope to launch a web-based program in January."
Still, much work remains to be done. "We were able to support our recommendations based on the quality of the evidence," said Dr. Flume. "But also we could see clearly where we were lacking data. This will allow us to lay the foundation for how those studies should be performed."
The committee plans to update the guidelines every five years.
American Thoracic Society
"Physicians treating patients with CF are faced with a growing number of treatment options" wrote lead author of the guidelines, Patrick A. Flume, M.D. "We are hopeful that clinicians will find these recommendations to be useful in their care of patients with CF."
The pulmonary guidelines committee assessed the clinical efficacy and safety of the use of aerosolized antibiotics, recombinant human DNase (dornase alfa), hypertonic saline inhalation, anti-inflammatory agents, macrolide antibiotics, the use of bronchodilators and N-acetylcysteine. They analyzed the clinical results with regard to the number of studies, strength of the study designs and the quality and consistency of results to make their final recommendations. Because of the general dearth of studies on treatments in children under the age of six, the committee restricted their recommendations to CF patients six years of age and older.
The treatments with the strongest, most consistent results yielding an "A"-grade positive recommendation were:
* Inhaled tobramycin, an antibiotic, to suppress chronic Pseudomonas aeruginosa infections in CF patients with moderate to severe disease to improve lung function and reduce exacerbations; and
* Dornase alfa, which degrades the free DNA that accumulates in CF mucus, thereby loosening the mucus, promoting airway clearance, improving lung function and reducing exacerbations.
"B" grade recommendations by the committee are for:
* Inhaled tobramycin, to suppress chronic Pseudomonas aeruginosa infections in CF patients with mild disease or who are asymptomatic, to reduce exacerbations;
* Dornase alfa, for CF patients with mild disease or who are asymptomatic, to improve lung function and reduce exacerbations;
* Hypertonic saline, which hydrates surface liquid in patients with CF, thereby improving lung function and decreasing exacerbations; and
* £]2-adrenergic receptor agonists, which relax smooth muscles and dilate bronchial passages, which improve lung-function in CF patients, and were well-tolerated.
The guidelines recommend against:
* Systemic corticosteroids in children because of "an excess number of adverse events," including abnormalities in glucose metabolism, cataracts, and percentage of patients "colonized" with Pseudomonas (this recommendation excludes patients who have concomitant asthma);
* Inhaled corticosteroids, because there was no clinical benefit (this recommendation excludes patients who have concomitant asthma); and
* Prophylactic anti-Staphylococcal antibiotics because of the lack of clinical efficacy and an apparent increase in P. aeruginosa infections with their use.
All other treatments lacked sufficient evidence to recommend for or against their use.
The article includes recommendations for physicians to help determine which therapies to use, and the order in which they should be introduced. "There is a challenge for the clinician to decide what therapy to start first, or when to add another therapy," explained Dr. Flume. "We are putting together an educational program to assist the community in implementation of the guidelines and hope to launch a web-based program in January."
Still, much work remains to be done. "We were able to support our recommendations based on the quality of the evidence," said Dr. Flume. "But also we could see clearly where we were lacking data. This will allow us to lay the foundation for how those studies should be performed."
The committee plans to update the guidelines every five years.
American Thoracic Society
Cystic Fibrosis News and Current Cystic Fibrosis Events RSSClearing the airways in cystic fibrosis
By manipulating the machinery used by our cells for quality control, researchers from the University of Pittsburgh have found a way to restore the function of cystic fibrosis (CF) airway cells.
PTC124 shows activity in cystic fibrosis; Phase 2 proof-of-concept data published in Lancet
New phase 2 data published today in The Lancet show that the investigational oral drug PTC124 demonstrates activity in nonsense-mutation cystic fibrosis (CF). The data show that treatment with PTC124 results in statistically significant improvements in the chloride channel function of patients with nonsense-mutation CF. The study was conducted at the Hadassah Hebrew University Hospital in Jerusalem, Israel and sponsored by PTC Therapeutics (PTC).
Breaking the 'mucus barrier' with a new drug delivery system
Chemical engineers from Johns Hopkins University have broken the "mucus barrier," engineering the first drug-delivery particles capable of passing through human mucus - regarded by many as nearly impenetrable - and carrying medication that could treat a range of diseases. Those conditions include lung cancer, cervical cancer and cystic fibrosis, the research noted in a presentation scheduled for the 236th National Meeting of the American Chemical Society.
NIH scientists find a novel mechanism that controls the development of autoimmunity
Scientists at the National Institutes of Health (NIH) have found a mechanism in the immune systems of mice that can lead to the development of autoimmune disease when turned off.
Researchers discover cell's 'quality control' mechanism
Researchers in Japan and Canada have discovered a key component of the quality control mechanism that operates inside human cells - sometimes too well. The breakthrough has significant implications for the development of new treatments for cystic fibrosis (CF) and some other hereditary diseases, the researchers say. Their results were published July 25 in the journal Science.
Most generalists reluctant to provide primary care for young adults with chronic illness
The majority of general internists and pediatricians in the United States are not comfortable serving as primary care providers for young adults with complex chronic illnesses that originate during childhood, according to findings from a new national survey.
Mucous breakthrough in mice holds promise for cystic fibrosis
A London, Canada scientist studying cystic fibrosis (CF) has successfully corrected the defect which causes the overproduction of intestinal mucous in mice.
Consortium develops new method to manipulate genetic material
A multi-institutional team of researchers, including scientists at the University of Minnesota Medical School, have developed a powerful tool for genomic research and medicine.
RNA emerges from DNA's shadow
RNA, the transporter of genetic information within the cell, has emerged from the shadow of DNA to become one of the hottest research areas of molecular biology, with implications for many diseases as well as understanding of evolution.
Should embryos with a hereditary disorder be transferred if no unaffected embryos are available?
The numbers of cycles of preimplantation genetic diagnosis or screening are rising steadily in Europe with over 2,700 reported in 2004 (the most recent year for which data are available).
More Cystic Fibrosis News Articles
 | Recipes for the Specific Carbohydrate Diet: The Grain-Free, Lactose-Free, Sugar-Free Solution to IBD, Celiac Disease, Autism, Cystic Fibrosis, and Other Health Conditions (Healthy Living Cookbooks) by Raman Prasad The Specific Carbohydrate Diet is a strict grain-free, lactose-free, and sucrose-free dietary regimen intended for those suffering from Crohn's disease and ulcerative colitis (both forms of IBD), celiac disease, IBS, cystic fibrosis, and autism. It is based on the work of Elaine Gottschall, who wrote Breaking the Vicious Cycle, which introduces the SCD and explains the importance of eliminating... |
 | The Troubled Dream of Genetic Medicine: Ethnicity and Innovation in Tay-Sachs, Cystic Fibrosis, and Sickle Cell Disease by Keith Wailoo, Stephen Pemberton Why do racial and ethnic controversies become attached, as they often do, to discussions of modern genetics? How do theories about genetic difference become entangled with political debates about cultural and group differences in America? Such issues are a conspicuous part of the histories of three hereditary diseases: Tay-Sachs, commonly identified with Jewish Americans; cystic fibrosis, often... |
 | The Power of Two: A Twin Triumph over Cystic Fibrosis by Isabel Stenzel Byrnes, Anabel Stenzel The tragedy of cystic fibrosis has been touchingly recounted before, but this is the first book to portray the symbiotic relationship between twins who share this life-threatening disease through adulthood. Isabel Stenzel Byrnes and Anabel Stenzel tell of their struggle to pursue normal lives while grappling with the realization that they might die young. Their story reflects the physical and... |
 | Sick Girl Speaks!: Lessons and Ponderings Along the Road to Acceptance by Tiffany Christensen Surprise! I’m still not dead! Okay, sure, I was born with an incurable genetic disease and, yes, I have faced terminal illness two times but … here I am! And I’m ready to speak! I’ve now been navigating the Western medical maze for over three decades. Along the way, I’ve had to learn some pretty painful lessons about how to advocate for myself and what happens if I don’t. I also know how scary... |
 | Parenting Children With Health Issues: Essential Tools, Tips, and Tactics for Raising Kids With Chronic Illness, Medical Conditions, and Special Healthcare Needs by Foster W. Cline, Lisa Greene 2008 Gold Winner of the Mom's Choice Awards, 2008 Winner of the Indie Excellence Awards for Parenting and Family, and 2007 Finalist for Foreword Magazine's Book of the Year! Special parenting skills are needed to raise kids with special needs. Whether your child struggles with allergies, asthma, diabetes, cystic fibrosis, an eating disorder or any other health issue, you will find the essential... |
 | As Long as We Both Shall Live: Two Novels by Lurlene Mcdaniel A change is coming, April Lancaster’s fortune cookie reads. Be prepared. But how could she be prepared for the news that she has an inoperable brain tumor? April’s life will never be the same. Then she meets handsome Mark Gianni. Mark has cystic fibrosis, but he also has a passion for life . . . and for April. When he asks April to marry him, she’s happier than she’s ever... |
 | Alex: The Life of a Child by Frank Deford Alexandra Deford, a precious and precocious girl, was just eight years old when she died in 1980 following a battle against the debilitating effects of cystic fibrosis, the number-one genetic killer of children. Her poignant and uplifting story touched the hearts of millions when it was first published and then made into a memorable television movie. A new introduction contains information... |
 | With Every Breath: stories by and about people living with cystic fibrosis Over 30,000 people in the US have cystic fibrosis, a life-threatening genetic disease that affects the lungs and digestive system. Physically, fighting it is a very perilous struggle. Emotionally, coping can oftentimes be even harder. With Every Breath consists of stories by and about people living with cystic fibrosis. Created to motivate, inspire, and generate positivity for those living... |
 | Taking Flight: Inspirational Stories of Lung Transplantation Lung Transplantation is still relatively new compared to other transplantation surgery. The first successful heart/lung transplant took place in 1981, with the first successful single lung transplant taking place in 1983. It was not until 1986 the first successful double lung transplant takes place. Even more recent is the living lobar transplant which the first successful one being in 1990. The... |
 | Forever Changes by Brendan Halpin 5:30 a.m., Brianna Pelletier gets ready for her daily pounding. As she lies on the couch, her dad beats her chest, then her back, coaxing the mucus out of her lungs. The pounding doesn’t take care of everything. Brianna’s held out for a long time, but a body with cystic fibrosis doesn’t last forever. It doesn’t matter that Brianna has a brilliant mathematical mind or that... |
| © 2008 BrightSurf.com |